Clinical Trial Status Differentiates Biotechs

Santini, Laura
February 2004
Investment Dealers' Digest;2/23/2004, Vol. 70 Issue 8, p11
Trade Publication
Discusses how the status of clinical trials affects the share price of biotech companies after going public. Success of the initial public offering (IPO) of Eyetech Pharmaceuticals Inc.; Contrast with the IPO of GTx Inc.; Rethinking among investment bankers in the wake of contrasting results.


Related Articles

  • GTx Offering to Add $40M, Rebuild Reserves, Buy Time. Wall, Tom // BioWorld Today;10/28/2010, Vol. 21 Issue 209, p1 

    This article focuses on the public offering issued by GTx Inc. to raise 40 million U.S. dollars and rebuild declining cash reserves. There is a plan by GTx to sell 14.3 million shares of common stock at 2.80 U.S. dollars per share. A 30-day option was granted by GTx to Lazard Capital Markets LLC...

  • Pharmasset Prices IPO Lower Than Expected To Raise $45M. Boggs, Jennifer // BioWorld Today;4/30/2007, Vol. 18 Issue 83, p1 

    The article reports that Pharmasset Inc. has set a $9 per share price for its initial public offering (IPO). The company aims to raise $45 million from the IPO. Previously, the company priced its shares between $12 and $14, but reduced it to $9 in relation to the Phase II program for clevudine....

  • Insmed Prices $26M Offering Focusing on CF lung infections. Winter, Peter // BioWorld Today;10/1/2012, Vol. 23 Issue 190, p1 

    The article reports on the pricing by Insmed Inc. of a 26 million U.S. dollar direct public offering of 6.3 million shares of its common stock. By October 31, 2012, Insmed intends to close the deal which will also offer additional shares of its common stock up to two million U.S. dollars....

  • Bioheart squeezes out meager $5.8 million in public offering. Morrison, Trista // Medical Device Daily;2/22/2008, Vol. 12 Issue 36, p2 

    The article deals with the completion of the initial public offering (IPO) of Bioheart in February 2008. The $1.1 million IPO closed at $5.25 per share price, which was reportedly below the $35 million the company had initially hoped for. As of September 30, 2007, the company posted a $9.5...

  • Tranzyme Prices IPO for GI Drug Development. Shaffer, Catherine // BioWorld Today;4/5/2011, Vol. 22 Issue 65, p2 

    The article reports on the pricing by Tranzyme Inc. of an initial public offering (IPO) which intends to raise 54 million U.S. dollars to support its pipeline of drugs for gastrointestinal motility disorders. On the Nasdaq stock exchange, the ticker symbol TZM will be adopted by Tranzyme. It...

  • 'Regado' Nuff Money Now? IPO Brings $43M to Push Phase III. Osborne, Randy // BioWorld Today;8/23/2013, Vol. 24 Issue 162, p1 

    The article reports on the initial public offering (IPO) launched by biopharmaceutical firm Regado Biosciences Inc. in 2013. The IPO will enable the firm to proceed with the Phase III trial of REG1, an anticoagulation system. As of August 22, 2013, Regado shares rose by 17.5% to 4.70 dollars....

  • Galena Prices $35M Offering to fund Breast Cancer Drug. Shaffer, Catherine // BioWorld Today;9/16/2013, Vol. 24 Issue 177, p1 

    The article discusses the underwritten public offering of pharmaceutical company Galena Biopharma Inc. of 17.5 million units of stock priced at 2 dollars per unit which will be utilized for the commercialization and launching of the drug Abstral sublingual tablets and funds for the Phase III...

  • Repros Lifts Weighty Offering: $71M for Hypogonadism Work. Osborne, Randy // BioWorld Today;6/21/2013, Vol. 24 Issue 119, p1 

    The article informs that Repros Therapeutics Inc. has set the price of an underwritten public offering at 19 dollars and raises the shares value from 3.7 million to 71.2 million shares. It mentions that the company has announced his after the success of the company's second Phase III trail for...

  • Geron Seeking $50M Plus to Support More Trials. Hollingsworth, Catherine // BioWorld Today;2/17/2009, Vol. 20 Issue 30, p1 

    The article reports on the goal of Geron Corp. to raise more than $50 million to support clinical trials, research and development and other activities. It has priced a public stock offering of 7.25 million shares as part of the effort. It is expected that the offering will close on February 19,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics